The standard "short" course treatment for tuberculosis (TB) is isoniazid, rifampicin, pyrazinamide and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered cured at six months. Tuberculosis (commonly shortened to TB) is an infection caused by the bacterium Mycobacterium tuberculosis, which most commonly affects the lungs (pulmonary TB) but can also affect the central nervous system (meningitis), lymphatic system, circulatory system (Miliary tuberculosis), genitourinary system, bones and joints. ... Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ... Rifampicin (INN) (IPA: ) or rifampin (USAN) is a bacteriocidal antibiotic drug of the rifamycin group. ... Pyrazinamide is an antituberculosis agent used to treat tuberculosis in afflicted patients. ... A bacteriostatic antimycobacterial prescribed to treat Tuberculosis (Mycobacterium). ...

The standard treatment for latent TB is six to nine months of isoniazid alone.

Historical data show that active TB will kill about two of every three people affected if left untreated.

For all practical purposes, only patients with tuberculosis of the lungs can spread TB to other people. People may become infected with TB but not have active disease: such people are said to have latent TB infection (LTBI) and are not capable of passing the infection on to other people. The reason for treating people with LTBI is to prevent them progressing to active TB disease later in life (approximately 10% lifetime risk). The distinction is important because treatment options are different for the two groups.

Medical Treatment of Tuberculosis

Treatment for tuberculosis should be administered by a medical practitioner experienced and trained in the treatment of tuberculosis. The standard "short" course treatment for tuberculosis where the sensitivities of the organism are not known, is isoniazid, rifampicin, pyrazinamide and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered cured at six months. Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ... Rifampicin (INN) (IPA: ) or rifampin (USAN) is a bacteriocidal antibiotic drug of the rifamycin group. ... Pyrazinamide is an antituberculosis agent used to treat tuberculosis in afflicted patients. ... A bacteriostatic antimycobacterial prescribed to treat Tuberculosis (Mycobacterium). ...

If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin and pyrazinamide (omitting ethambutol) for two months, then isoniazid and rifampicin for four months.

Abbreviations

Anti-tuberculous drug names are abbreviated in a standard manner.

• Streptomycin is STM or S,
• p-aminosalicyclic acid is PAS or P.
• Isoniazid is INH or H,
• Rifampicin is RMP or R (but some US publications use RIF),
• Ethambutol is EMB or E,
• Pyrazinamide is PZA or Z,

Drug regimens are similarly abbreviated in a standardised manner. The drugs are listed using their single letter abbreviations (in the order given above, which is roughly the order of introduction into clinical practice). A prefix denotes the number of months the treatment should be given for; a subscript denotes intermittent dosing (so ₃ means three times a week) and no subscript means daily dosing. Most regimens have an initial high-intensity phase, followed by a continuation phase (also called a consolidation phase or eradication phase): the high-intensity phase is given first, then the continuation phase, the two phases divided by a slash. Streptomycin is an antibiotic drug, the first of a class of drugs called aminoglycosides to be discovered, and was the first antibiotic remedy for tuberculosis. ... Aminosalicylic acid (C7H7NO3) is also known as para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, PAS or P. It is sold in the US by Jacobus Pharmaceutical as Paser®. 5-aminosalicylic acid is a closely related compound that also has medical uses. ... Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ... Rifampicin (INN) (IPA: ) or rifampin (USAN) is a bacteriocidal antibiotic drug of the rifamycin group. ... A bacteriostatic antimycobacterial prescribed to treat Tuberculosis (Mycobacterium). ... Pyrazinamide is an antituberculosis agent used to treat tuberculosis in afflicted patients. ...

So,

2HREZ/4HR₃

means isoniazid, rifampicin, pyrazinamide daily (with either ethambutol or streptomycin) for two months, followed by four months of isoniazid and rifampicin given thrice weekly.

These standard abbreviations are used in the rest of this article.

Other drugs used in TB treatment are:

• Amikacin abbreviated AK
• Clarithromycin or CLR
• Linezolid or LZD
• Moxifloxacin or MXF
• Thioacetazone or T

Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. ... Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex or... Linezolid is a synthetic systemic antibiotic drug. ... Moxifloxacin is a synthetic flouroquinolone antibiotic agent. ...

Treatment regimens

Tuberculosis has been treated with combination therapy for over fifty years. Drugs are not used singly (except in latent TB or chemoprophylaxis), and regimens that use only single drugs result in the rapid development of resistance and treatment failure.^[1] The rationale for using multiple drugs to treat TB are based on simple probability. The frequency of spontaneous mutations that confer resistance to an individual drug are well known: 1 in 10⁷ for EMB, 1 in 10⁸ for STM and INH, and 1 in 10¹⁰ for RMP.^[2] Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ...

A patient with extensive pulmonary TB has approximately 10¹² bacteria in his body, and therefore will probably be harboring approximately 10⁵ EMB-resistant bacteria, 10⁴ STM-resistant bacteria, 10⁴ INH-resistant bacteria and 10² RMP-resistant bacteria. Resistance mutations appear spontanously and independently, so the chances of him harbouring a bacterium that is spontaneously resistant to both INH and RMP is 1 in 10⁶, and the chances of him harbouring a bacterium that is spontaneously resistant to all four drugs is 1 in 10¹¹. This is, of course, an oversimplification, but it is a useful way of explaining combination therapy.

There are other theoretical reasons for supporting combination therapy. The different drugs in the regimen have different modes of action: INH and EMB are bacteriostatic (they stop the bacteria replicating, but do not kill them); RMP is bacteriocidal (it actually kills bacteria).

All TB regimens in use were 18 months or longer until the appearance of rifampicin. In 1953, the standard UK regimen was 3SPH/15PH or 3SPH/15SH₂. Between 1985 to 1970, EMB replaced PAS. RMP began to be used to treat TB in 1968 and the BTS study in the 1970's showed that 2HRE/7HR was efficacious. In 1984, a BTS study showed that 2HRZ/4HR was efficacious,^[3] with a relapse rate of less than 3% after two years.^[4] In 1995, with the recognition that INH resistance was increasing, the BTS recommended adding EMB or STM to the regimen: 2HREZ/4HR or 2SHRZ/4HR, which are the current regimens. The WHO also recommend a six month continuation phase of HR if the patient is still culture positive after 2 months of treatment (approximately 15% of patients with fully-sensitive TB) and for those patients who have extensive bilateral cavitation at the start of treatment.

There is evidence supporting some deviations from the standard regimen when treating pulmonary TB. Sputum culture negative patients do well on only 3 months of treatment (possibly because some of these patients never had TB at all). Sputum culture positive patients who are smear negative at the start of treatment do well with only 4 months of treatment (this has not been validated for HIV-positive patients). It is unwise to treat patients for only three or four months, but all TB physicians will have patients who stop their treatment early (for whatever reason), and it can be re-assuring to know that sometimes retreatment is unnecessary. Elderly patients who are already taking a large number of tablets may be offered 9HR, omitting PZA which is the bulkiest part of the regimen.

It may not always be necessary to treat with four drugs from the beginning. An example might be a close contact of a patient known to have a fully-sensitive strain of tuberculosis: in this case, it may be acceptable to use 2HRZ/4HR (omitting EMB or STM) in the expectation that their strain will be INH susceptible also.

The current regimen has been validated for adults with pulmonary TB but is also used to treat TB in the rest of the body (except infection of the brain or spinal cord). The US recommendation is 2HRZ/7HR for extra-pulmonary TB, but this recommendation is based on slim evidence and is not supported by the WHO. The only published evidence for 2HRZ/7HR is for TB osteomyelitis in weight-bearing bones. For other meanings of the acronym WHO, see WHO (disambiguation) WHO flag Headquartered in Geneva, Switzerland, the World Health Organization (WHO) is an agency of the United Nations, acting as a coordinating authority on international public health. ...

TB involving the brain or spinal cord (meningitis, encephalitis, etc.) is currently treated with 2HREZ/10HR (12 months of treatment in total), but there is no evidence to say that this is superior to 2HREZ/4HR, it is merely that no-one has been brave enough to do the clinic trial that answers the question if the short course is equivalent. Meningitis is inflammation of the membranes (meninges) covering the brain and the spinal cord. ... Encephalitis is an acute inflammation of the brain, commonly caused by a viral infection. ...

Treatment monitoring and DOTS

DOTS stands for "Directly Observed Therapy, Short-course" and is a major plank in the WHO global TB eradication programme. The WHO advise that all TB patients should have at least the first two months of their therapy observed (and preferably the whole of it observed): this means an independent observer watching tuberculosis patients swallow their anti-TB therapy. The independent observer is often not a healthcare worker and may be a shopkeeper or a tribal elder or similar senior person within that society. DOTS is used with intermittent dosing (thrice weekly or 2HREZ/4HR₃). The WHO does not recommend twice weekly dosing (2HREZ/4HR₂), not because it is ineffective, but because there is no margin for error (accidentally omitting one dose per week results in once weekly dosing, which is ineffective). For other meanings of the acronym WHO, see WHO (disambiguation) WHO flag Headquartered in Geneva, Switzerland, the World Health Organization (WHO) is an agency of the United Nations, acting as a coordinating authority on international public health. ...

Treatment with properly implemented DOTS has a success rate exceeding 95% and prevents the emergence of further multi-drug resistant strains of tuberculosis.

Some people recommend monthly surveillance until cultures convert to negative; this does not form any part of the UK or WHO recommendations for TB. If cultures are positive or symptoms do not resolve after three months of treatment, it is necessary to re-evaluate the patient for drug-resistant disease or nonadherence to drug regimen. If cultures do not convert to negative despite three months of therapy, consider initiating directly observed therapy.

Non-compliance with Tuberculosis Treatment

Patients who take their TB treatment in an irregular and unreliable way are at greatly increased risk of treatment failure, relapse and the development of drug-resistant TB strains.

There are variety of reasons why patients fail to take their medication. The symptoms of TB commonly resolve within a few weeks of starting TB treatment and many patients then lose motivation to continue taking their medication. Regular follow-up is important to check on compliance and to identify any problems patients are having problems with their medication. Patients need to be told of the importance of taking their tablets regularly, and the importance of completing treatment, because of the risk of relapse or drug-resistance developing otherwise.

One of the main complaints is the bulkiness of the tablets. The main offender is PZA, the tablets being the size of horse tablets. PZA syrup can be offered as a substitute, or if the size of the tablets is truly an issue and liquid preparations are not available, then PZA can be omitted altogether. If PZA is omitted, the patient should be warned that this results in a significant increase in the duration of treatment (details of regimens omitting PZA are given below).

It is possible to test urine for isoniazid and rifampicin levels in order to check for compliance. The interpretation of urine analysis is based on the fact that isoniazid has a longer half-life than rifampicin:

• urine positive for isoniazid and rifampicin patient probably fully compliant
• urine positive for isoniazid only patient has taken his medication in the last few days preceding the clinic appointment, but had not yet taken a dose that day.
• urine positive for rifampicin only patient has omitted to take his medication the preceding few days, but did take it just before coming to clinic.
• urine negative for both isoniazid and rifampicin

In countries where doctors are unable to compell patients to take their treatment (e.g., the UK), some say that urine testing only results in unhelpful confrontations with patients and does not help increase compliance. In countries where legal measures can be taken to force patients to take their medication (e.g., the US), then urine testing can a useful adjunct in assuring compliance.

RMP colours the urine and all bodily secretions (tears, sweat, etc.) an orange-pink colour and this can be a useful proxy if urine testing is not available (although this colour fades approximately six to eight hours after each dose).

Extra-pulmonary tuberculosis

Tuberculosis not affecting the lungs is called extra-pulmonary tuberculosis. Disease of the central nervous system is specifically excluded. A diagram showing the CNS: 1. ...

The UK and WHO recommendation is 2HREZ/4HR; the US recommendation is 2HREZ/7HR. There is no published evidence to support the use of one regimen over the other. The majority of clinical trials on tuberculosis treatment are for pulmonary TB and no treatment regimen has been validated for extra-pulmonary TB. The difference in recommendations reflects a difference in opinion and not evidence. For other meanings of the acronym WHO, see WHO (disambiguation) WHO flag Headquartered in Geneva, Switzerland, the World Health Organization (WHO) is an agency of the United Nations, acting as a coordinating authority on international public health. ...

Up to 25% of patients with TB of the lymph nodes (TB lymphadenitis) will get worse on treatment before they get better, and this happens over a number of months. This is a common reason for patients (and their physicians) to panic unncessarily. Steroids may sometimes be useful in these instances, but are not necessary. No change to the treatment regimen is necessary.

CNS tuberculosis

Tuberculosis may affect the central nervous system (meninges, brain or spinal cord) in which case it is called TB meningitis, TB cerebritis, and TB myelitis respectively; 12 months of treatment is given (2HREZ/10HR). Diagnosis is especially difficult as CSF culture is positive in less than half of cases, and therefore a large proportion of cases are treated on the basis of clinical suspicion alone. TB cerebritis (or TB of the brain) may require brain biopsy in order to make the diagnosis: this is not always available and even when it is, some clinicians would debate whether it is justified putting a patient through such an invasive procedure when a trial of anti-TB therapy may be preferable. It is possible that shorter durations of therapy (e.g. six months) may be sufficient, but no clinical trial has addressed this issue. CSF of patients with treated TB meningitis is commonly abnormal (even at 12 months); CSF abnormality bears no correlation with clinical progress,^[5] and is not an indication for extending or repeating treatment; repeated sampling of CSF by lumbar puncture to monitor treatment progress should therefore not be done. Tuberculous meningitis is also called TB meningitis. Tuberculous meningitis is Mycobacterium tuberculosis infection of the meninges. ... Cerebrospinal fluid (CSF), Liquor cerebrospinalis, is a clear bodily fluid that occupies the subarachnoid space in the brain (the space between the skull and the cerebral cortex—more specifically, between the arachnoid and pia layers of the meninges). ...

CNS TB may be secondary to blood-borne spread: therefore some experts advocate the routine sampling of CSF in patients with miliary TB.^[6] Miliary tuberculosis (not military tuberculosis) is a form of tuberculosis that is characterized by a wide dissemination into the human body and by the tiny size of the lesions. ...

The anti-TB drugs that are most useful for the treatment of CNS TB are:

• INH (CSF penetration 100%)
• RMP (10–20%)
• EMB (25–50% inflamed meninges only)
• PZA (100%)
• STM (20% inflamed meninges only)
• LZD (20%)
• Cycloserine (80–100%)
• Ethionamide (100%)
• PAS (10–50%)

The use of steroids is routine in TB meningitis (see section below). Cerebrospinal fluid penetration is the proportion of drug that crosses the blood-brain barrier to enter the cerebrospinal fluid. ... Linezolid is a synthetic systemic antibiotic drug. ... This article or section does not cite its references or sources. ... Aminosalicylic acid (C7H7NO3) is also known as para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, PAS or P. It is sold in the US by Jacobus Pharmaceutical as Paser®. 5-aminosalicylic acid is a closely related compound that also has medical uses. ...

Steroids in TB

The use of corticosteroids (e.g., prednisolone or dexamethasone) in the treatment is TB is proven for TB meningitis and TB pericarditis. The dose for TB meningitis is dexamethasone 8 to 12mg daily tapered off over six weeks (for those who prefer more precise dosing, please see Thwaites, 2004^[7]). The dose for pericarditis is prednisolone 60mg daily tapered off over four to eight weeks. In physiology, corticosteroids are a class of steroid hormones that are produced in the adrenal cortex. ... Prednisolone is a synthetic corticosteroid drug which is usually taken orally and can be used for a large number of different conditions. ... Dexamethasone is a synthetic member of the glucocorticoid class of hormones. ... Meningitis is inflammation of the membranes (meninges) covering the brain and the spinal cord. ... Pericarditis is inflammation of the pericardium. ...

Steroids may be of temporary benefit in pleurisy, extremely advanced TB, and TB in children:

• Pleurisy: prednisolone 20 to 40mg daily tapered off over 4 to 8 weeks
• Extremely advanced TB: 40 to 60mg daily tapered off over 4 to 8 weeks
• TB in children: 2 to 5mg/kg/day for one week, 1mg/kg/day the next week, then tapered off over 5 weeks

Steroids may be of benefit in peritonitis, miliary disease, laryngeal TB, lymphadenitis and genitourinary disease, but the evidence is scant and the routine use of steroids cannot be recommended. Steroid treatment in these patients should be considered on a case by case basis by the attending physician. Miliary tuberculosis (not military tuberculosis) is a form of tuberculosis that is characterized by a wide dissemination into the human body and by the tiny size of the lesions. ...

Thalidomide may be of benefit in TB meningitis and has been used in cases where patients have failed to respond to steroid treatment.^[8] Alan Pharmaceuticals is a key supplier of thalidomide worldwide. ...

Adverse effects of TB treatment

For information on adverse effects of individual anti-TB drugs, please refer to the individual articles for each drug.

The relative incidence of major adverse effects has been carefully described^[9]:

• INH 0.49 per hundred patient months
• RMP 0.43
• EMB 0.07
• PZA 1.48
• All drugs 2.47

This works out to an 8.6% risk that any one patient will need to have his drug therapy changed during the course of standard short-course therapy (2HREZ/4HR). The people identified to be most at risk of major adverse side effects in this study were:

• age >60,
• females,
• HIV positive patients, and
• Asians.

It can be extremely difficult identifying which drug is responsible for which side effect, but the relative frequency of each is known^[10]. The offending drugs are given in decreasing order of frequency:

• Thrombocytopaenia: RMP
• Neuropathy: INH
• Vertigo: SM
• Hepatitis: PZA, RMP, INH
• Rash: PZA, RMP, EMB

Thrombocytopaenia is only caused by RMP and no test dosing need be done. Regimens omitting RMP are discussed below. Please refer to the entry on rifampicin for further details. Thrombocytopenia (or -paenia, or thrombopenia in short) is the presence of relatively few platelets in blood. ... Rifampicin (INN) (IPA: ) or rifampin (USAN) is a bacteriocidal antibiotic drug of the rifamycin group. ...

The most frequent cause of neuropathy is INH. The peripheral neuropathy of INH is always a pure sensory neuropathy and finding a motor component to the peripheral neuropathy should always prompt a search for an alternative cause. Once a peripheral neuropathy has occurred, INH must be stopped and pyridoxine should be given at a dose of 50mg thrice daily. Simply adding high dose pyridoxine to the regimen once neuropathy has occured will not stop the neuropathy from progressing. Patients at risk of peripheral neuropathy from other causes (diabetes mellitus, alcoholism, renal failure, malnutrition, pregnancy, etc.) should all be given pyridoxine] 10mg daily at the start of treatment. Please refer to the entry on isoniazid for details on other neurological side effects of INH. Peripheral neuropathy is the medical term for damage to nerves of the peripheral nervous system, which may be caused either by diseases of the nerve or from the side-effects of systemic illness. ... For the disease characterized by excretion of large amounts of severely diluted urine, see diabetes insipidus. ... Alcoholism is the compulsive consumption of alcohol. ... Renal failure is the condition where the kidneys fail to function properly. ... The two major forms of vitamin B6 are pyridoxine and pyridoxamine. ... Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ...

Rashes are most frequently due to PZA, but can occur with any of the TB drugs. Test dosing using the same regimen as detailed below for hepatitis may be necessary to determine which drug is responsible. RMP commonly causes itching without a rash in the first two weeks of treatment: treatment should not be stopped and the patient should be advised that the itch usually resolves on its own.

Fever during treatment can be due to a number of causes. It can occur as a natural effect of tuberculosis (in which case it should resolve within three weeks of starting treatment). Fever can be a result of drug resistance (but in that case the organism must be resistant to two or more of the drugs). Fever may be due to a superadded infection or additional diagnosis (patients with TB are not exempt from getting influenza and other illnesses during the course of treatment). In a few patients, the fever is due to drug allergy. The clinician must also consider the possibility that the diagnosis of TB is wrong. If the patient has been on treatment for more than two weeks and if the fever had initially settled and then come back, it is reasonable to stop all TB medication for 72 hours. If the fever persists despite stopping all TB medication, then the fever is not due to the drugs. If the fever disappears off treatment, then the drugs need to be tested individually to determine the cause. The same scheme as is used for test dosing for drug-induced hepatitis (described below) may be used. The drug most frequently implicated as causing a drug fever is RMP: details are given in the entry on rifampicin. Rifampicin (INN) (IPA: ) or rifampin (USAN) is a bacteriocidal antibiotic drug of the rifamycin group. ...

Drug-induced hepatitis

The single biggest problem with TB treatment is drug-induced hepatitis. Three drugs can induce hepatitis: PZA, INH and RMP (in decreasing order of frequency) ^[1][11]. It is not possible to distinguish between these three causes based purely on of signs and symptoms. Test dosing must be carried out to determine which drug is responsible (this is discussed in detail below).

Liver function tests (LFTs) should be checked at the start of treatment, but, if normal, need not be checked again; the patient need only be warned of the symptoms of hepatitis. Some clinicians insist on regular monitoring of LFT's while on treatment, and in this instance, tests need only be done two weeks after starting treatment and then every two months thereafter, unless any problems are detected. Liver function tests (LFTs or LFs), which include liver enzymes, are groups of clinical biochemistry laboratory blood assays designed to give a doctor or other health professional information about the state of a patients liver. ...

Elevations in bilirubin must be expected with RMP treatment (RMP blocks bilirubin excretion) and usually resolve after 10 days (liver enzyme production increases to compensate). Isolated elevations in bilirubin can be safely ignored.

Elevations in liver transaminases (ALT and AST) are common in the first three weeks or treatment. If the patient is asymptomatic and the elevation is not excessive then no action need be taken; some experts suggest a cut-off of four times the upper limit of normal, but there is no evidence to support this particular number over and abother any other number. Some experts consider that treatment should only be stopped if jaundice becomes clinically evident. Alanine transaminase or ALT is an enzyme (EC 2. ... Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic Transaminase (SGOT) or aspartate aminotransferase (ASAT) (EC 2. ...

If clinically significant hepatitis occurs while on TB treatment, then all the drugs should be stopped until the liver transaminases return to normal. If the patient is so ill that TB treatment cannot be stopped, then STM and EMB should be given until the liver transaminases return to normal (these two drugs are not associated with hepatitis).

Fulminant hepatitis can occur in the course of TB treatment, but is fortunately rare; emergency liver transplantation may be necessary and deaths do occur.

Test dosing for drug-induced hepatitis

Drugs should be re-introduced individually. This cannot be done in an outpatient setting, and must be done under close observation. A nurse must be present to take patient's pulse and blood pressure at 15 minutes intervals for a minimum or four hours after each test dose is given (most problems will occur within six hours of test dosing, if they are going to occur). Patients can become very suddenly unwell and access to intensive care facilities must be available. The drugs should be given in this order:

• Day 1: INH at 1/3 or 1/4 dose
• Day 2: INH at 1/2 dose
• Day 3: INH at full dose
• Day 4: RMP at 1/3 or 1/4 dose
• Day 5: RMP at 1/2 dose
• Day 6: RMP at full dose
• Day 7: EMB at 1/3 or 1/4 dose
• Day 8: EMB at 1/2 dose
• Day 9: EMB at full dose

No more than one test dose per day should be given, and all other drugs should be stopped while test dosing is being done. So on day 4, for example, the patient only receives RMP and no other drugs are given. If the patient completes the nine days of test dosing, then it is reasonable to assume that PZA has caused the hepatitis and no PZA test dosing need be done.

The reason for using the order for testing drugs is because the two most important drugs for treating TB are INH and RMP, so these are tested first: PZA is the most likely drug to cause hepatitis and is also the drug that can be most easily omitted. EMB is useful when the sensitivity pattern of the TB organism are not known and can be omitted if the organism is known to be sensitive to INH. Regimens omitting each of the standard drugs are listed below.

The order in which the drugs are tested can be varied according to the following considerations:

1. The most useful drugs (INH and RMP) should be tested first, because the absence of these drugs from a treatment regimen severely impairs its efficacy.
2. The drugs most likely to be causing the reaction should be tested as late as possible (and possibly need not be tested at all). The avoids rechallenging patients with a drug to which they have already had a (possibly) dangerous adverse reaction.

A similar scheme may be used for other adverse effects (such as fever and rash), using similar principles.

Alternative regimens

Regimens omitting isoniazid

Isoniazid resistance in the UK accounts for approximately 6 to 7% of isolates at time of writing (25 Feb 2006). Worldwide, it is the most common type of resistance encountered, hence the current recommendation of using HREZ at the beginning of treatment until sensitivities are known. It is useful to know of current reported outbreaks (like the current outbreak of INH-resistant TB in London).

If a patient is discovered to be infected with an isoniazid-resistant strain of TB having completed 2 months of HREZ, then he should be changed to RE for a further 10 months. If the patient is intolerant to isoniazid, then a reasonable regimen is 2REZ/10RE (although 2REZ/7RE may be acceptable if the patient is well supervised). The US recommendation is 6RZE with the option of adding a quinolone such as moxifloxacin. The level of evidence for all these regimens is poor, and there is little to recommend one over the other.

Regimens omitting rifampicin

It is rare for TB strains to be resistant to rifampicin without being resistant to isoniazid, but rifampicin intolerance is not uncommon (hepatitis or thrombocytopaenia being the most common reasons for stopping rifampicin). Rifampicin is the most potent sterilising drug available for the treatment of tuberculosis and all treatment regimens that omit rifampicin are significantly longer than the standard regimen.

The UK recommendation is 18HE or 12HEZ. The US recommendation is 9 to 12HEZ, with option of adding a quinolone.

Regimens omitting pyrazinamide and treatment of M. bovis

PZA is a common cause of hepatitis and of painful arthralgia in the HREZ regimen, and can be safely stopped in those patients who are intolerant to it. Isolated PZA resistance is uncommon, but M. bovis is innately resistant to PSA. Binomial name Mycobacterium bovis Mycobacterium bovis is a type of bacterium that causes tuberculosis in cattle. ... Arthralgia is a term used to describe pain in the joints. ...

There is good evidence from UK trials that in these patients, a regimen of 9HR is adequate. This is the regimen used to treat M. bovis.

Regimens omitting ethambutol

EMB intolerance or resistance is rare. If a patient is truly intolerant or is infected with TB that is resistant to EMB, then 2HRZ/4HR is a perfectly acceptable regimen. EMB has no part to play in the treatment of INH and RMP sensitive TB, and the only reason for including it in the initial regimen is because of increasing rates of INH resistance. If INH resistance rates are known to be low or if the infecting TB strain is known to be INH-sensitive, then there is no need to use EMB anyway.

Tuberculosis and other conditions

Tuberculosis and liver disease

It should be noted that patients with alcoholic liver disease are at an increased risk of tuberculosis. The incidence of tuberculous peritonitis is particularly high in patients with cirrhosis of the liver.

No dosing change needs to be made in the dosing of patients with known liver disease, unless the liver disease is thought to have been caused by TB treatment. Some authorities recommend avoiding PZA in patients with known alcoholic liver disease.

Patients with pre-existing liver disease should have their liver function tests monitored regularly throughout TB treatment.

Drug-induced hepatitis is discussed in a separate section above.

Tuberculosis and pregnancy

Pregnancy itself is not a risk factor for TB.

Women on the oral contraceptive pill must be warned that the rifampicin will make it less effective. Women should not stop taking the oral contraceptive pill while being treated for TB, but should use additional precautions (e.g., condoms) for the duration of treatment. Oral contraceptives are contraceptives which are taken orally and inhibit the bodys fertility by chemical means. ...

Untreated TB in pregnancy is associated with an increased risk of miscarriage and major foetal abnormality. The US guidelines recommend omitting PZA when treating TB in pregnancy; the UK and WHO guidelines make no such recommendation. There is extensive experience with the treatment of pregnant women with TB and no toxic effect of PZA in pregnancy has ever been found. High doses of RMP (much higher than used in humans) causes neural tube defects in animals, but no such effect has ever been found in humans. There may be an increased risk of hepatitis in pregnancy and during the puerperium. It is prudent to advise all women of child-bearing age to avoid getting pregnant until TB treatment is completed.

Aminoglycosides (STM, capreomycin, amikacin) cannot be used in pregnancy, because they cause deafness in the unborn child. Aminoglycosides are a group of antibiotics that are effective against certain types of bacteria. ... Streptomycin is an antibiotic drug, the first of a class of drugs called aminoglycosides to be discovered, and was the first antibiotic remedy for tuberculosis. ... A peptide Antibiotic which is given in combination with other antibiotics in tuberculosis adverse effects includes nephrotoxicity and 8th cranial nerve toxicity. ... Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. ...

Tuberculosis and kidney disease

Patients with renal failure have a 10 to 30-fold increase in risk of getting TB. Patients with kidney disease who are being given immunosuppressive drugs or are being considered for transplant should be considered for treatment of latent tuberculosis if appropriate. Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ...

Aminoglycosides (STM, capreomycin and amikacin) should be avoided in patients with mild to severe kidney problems because of the increased risk of damage to the kidneys. If the use of aminoglycosides cannot be avoided (e.g., in treating drug-resistant TB) then serum levels must be closely monitored and the patient warned to report any side-effects (deafness in particular). If patient have end-stage renal failure and have no useful remaining kidney function, then aminoglycosides can be used, but only if drug levels can be easily measured (often only amikacin levels can be measured).

In mild renal impairment, no change needs to be made in dosing any of the other drugs routinely used in the treatment of TB. In severe renal insufficiency (GFR<30), the EMB dose should be halved (or avoided altogether). The PZA dose is 20mg/kg/day (UK recommendation) or three-quarters the normal dose (US recommendation), but not much published evidence is available to support this. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal glomerular capillaries into Bowmans capsule per unit time. ...

When using 2HRZ/4HR in patients on dialysis, the drugs should be given daily during the intial high-intensity phase. In the continuation phase, the drugs should be given at the end of each haemodialysis session and no dose should be taken on non-dialysis days.

Tuberculosis and HIV

In patients with HIV, if possible, treatment for the HIV should be delayed until TB treatment is completed, if possible.

The UK guidance is

• CD4 count over 200—delay treatment until the six months of TB treatment are complete.
• CD4 count 100 to 200—delay treatment until the initial two month intensive phase of therapy is complete
• CD4 count less than 100—the situation is unclear and patients should be enrolled in clinical trials examining this question.

If HIV treatment has to be started while a patient is still on TB treatment, then the advice of a specialist HIV pharmacist should be sought. In general, there is no significant interactions with the NRTI's. Nevirapine should not be used with rifampicin. Efavirenz may be used, but dose used depends on the patient's weight (600mg daily if weight<50kg; 800mg daily if weight>50kg). Efavirenz levels check early after starting treatment (unfortunately, this is not a service routinely offered in the US, but is readily available in the UK). The protease inhibitors must be avoided if at all possible. Antiretroviral drugs are medications for the treatment of infection by the retrovirus HIV. Different antiretroviral drugs act at various stages of the HIV life cycle. ... Protease inhibitor can refer to: Protease inhibitor (pharmacology): a class of medication that inhibits viral protease Protease inhibitor (biology): a group of proteins that inhibit proteases. ...

Thioacetazone must not be used because the risk of potentially fatal exfoliative dermatitis.

Tuberculosis and epilepsy

INH may be associated with an increased risk of seizures. Pyridoxine 10mg daily should be given to all epileptics taking INH. There is no evidence that INH causes seizures in patients who are not epileptic.

TB treatment involves numerous drug interactions with anti-epileptic drugs and serum drug levels should be closely monitored. There are serious interactions between rifampicin and carbamazepine, rifampicin and phenytoin, and rifampicin and sodium valproate. The advice of a pharmacist should always be sought.

Treatment of drug-resistant tuberculosis

Multidrug-resistant Tuberculosis

Multi-drug resistant tuberculosis (MDR-TB) is defined as TB that is resistant at least to INH and RMP. Isolates that are multiply-resistant to any other combination of anti-TB drugs but not to INH and RMP are not classed as MDR-TB. MDR-TB that is also resistant to three or more of the six classes of second-line drugs is called "extensively drug-resistant tuberculosis" or XDR-TB and is associated with a significantly poorer mortality rate.^[12]

A 1997 survery of 35 countries found rates above 2% in about a third of the countries surveyed. The highest rates were in the former USSR, the Baltic states, Argentina, India and China, and was associated with poor or failing national Tuberculosis Control programmes. Likewise, the appearance of high rates of MDR-TB in New York city the early 1990's was associated with the dismantling of public health programmes by the Reagan administration. Ronald Wilson Reagan (February 6, 1911 – June 5, 2004) was the 40th President of the United States (1981–1989) and the 33rd Governor of California (1967–1975). ...

MDR-TB can develop in the course of the treatment of fully sensitive TB and this is always the result of poor compliance with a course of TB treatment.

The treatment and prognosis of MDR-TB are much more akin to that for cancer than to that for an infection. It has a mortality rate of up to 80%, which depends on a number of factors, including (1) how many drugs the organism is resistant to (the fewer the better), (2) how many drugs the patient is given (should be five or more), (3) whether an aminoglycoside is given or not (should be given for the first three months at least), (4) the expertise and experience of the physician, (5) how co-operative the patient is with treatment, (6) whether the patient is HIV positive or not (HIV co-infection is associated with an increased mortality). Treatment courses are generally measured in months to years, may require surgery and despite that, the death rates are still high despite optimal treatment. Good outcomes are possible with optimal therapy.^[13]

The treatment of MDR-TB must be undertaken by a physician experienced in the treatment of MDR-TB. Mortality and morbidity in patients treated in non-specialist centres is significantly inferior to those patients treated in specialist centres.

In addition to the obvious risks (i.e., known exposure to a patient with MDR-TB), risk factors for MDR-TB include male sex, HIV infection, previous incarceration, failed TB treatment, failure to respond to standard TB treatment, and relapse following standard TB treatment.

Treatment of MDR-TB must be done on the basis of sensitivity testing: it is impossible to treat such patients without this information. If treating a patient with suspected MDR-TB, the patient should be started on SHREZ+moxifloxacin+cycloserine pending the result oflaboratory sensitivity testing.

A gene probe for rpoB is available in some countries and this serves as a useful marker for multidrug resistant TB, because isolated RMP resistance is rare (except when patients have a history of being treated with rifampicin alone). If the results of a gene probe (rpoB) are known to be positive, then it is reasonable to omit RMP and to use SHEZ+moxifloxacin+cycloserine. The reason for this is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective. The introduction to this article provides insufficient context for those unfamiliar with the subject matter. ...

When sensitivities are known and the isolate is confirmed as resistant to both INH and RMP, five drugs should be chosen in the following order (based on known sensitivities):

• STM, capreomycin, or amikacin
• PZA
• EMB
• Rifabutin
• Moxifloxacin (MXF)
• Cycloserine
• Prothionamide or ethionamide
• PAS
• Clarithromycin
• Linezolid
• high-dose INH (if low-level resistance)
• Interferon-γ
• Thioridazine
• R207910

Rifampicin resistance often means rifabutin resistance, but not always: the laboratory should be asked to test for it. If it is difficult finding five drugs to treat then the clinician can request that high level INH-resistance be looked for. If the strain has only low level INH-resistance, then high dose INH can be used as part of the regimen. When counting drugs, PZA and interferon count as zero; i.e., when adding PZA to a four drug regimen, you must still choose another drug to make five. It is not possible to use more than one aminoglycoside (STM, capreomycin or amikacin), because the toxic effect of these drugs is additive: if possible, the aminoglycoside should be given daily for a minimum of three months (and perhaps thrice weekly thereafter). Ciprofloxacin should no longer be used in the treatment of tuberculosis if moxifloxacin is available. Streptomycin is an antibiotic drug, the first of a class of drugs called aminoglycosides to be discovered, and was the first antibiotic remedy for tuberculosis. ... A peptide Antibiotic which is given in combination with other antibiotics in tuberculosis adverse effects includes nephrotoxicity and 8th cranial nerve toxicity. ... Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. ... Pyrazinamide is an antituberculosis agent used to treat tuberculosis in afflicted patients. ... A bacteriostatic antimycobacterial prescribed to treat Tuberculosis (Mycobacterium). ... Rifabutin is a drug used in the treatment of tuberculosis. ... Moxifloxacin is a synthetic flouroquinolone antibiotic agent. ... This article or section does not cite its references or sources. ... Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex or... Linezolid is a synthetic systemic antibiotic drug. ... Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ... Thioridazine is a piperidine phenothiazine antipsychotic drugs and is used in the treatment of schizophrenia and psychosis. ...

There is no intermittent regimen validated for use in MDR-TB, but clinical experience is that giving injectable drugs for five days a week (because there is no-one available to give the drug at weekends) does not seem to result in inferior results. Directly observed therapy certainly helps to improve outcomes in MDR-TB and should be considered an integral part of the treatment of MDR-TB.^[14]

Response to treatment must be obtained by repeated cultures (monthly if possible). Treatment for MDR-TB must be given for a minimum of 18 months and cannot be stopped until the patient has been culture-negative for a minimum of nine months. It is not unusual for patients with MDR-TB to be on treatment for two years or more.

Patients with MDR-TB should be isolated in negative-pressure rooms, if possible. Patients with MDR-TB should not be accommodated on the same ward as immunosuppressed patients (HIV infected patients, or patients on immunosuppressive drugs). Careful monitoring of compliance with treatment is crucial to the management of MDR-TB (and some physicians insist on hospitalisation if only for this reason). Some physicians will insist that these patients are isolated until their sputum is smear negative, or even culture negative (which may take many months, or even years). Keeping these patients in hospital for weeks (or months) on end may be a practical or physical impossibility and the final decision depends on the clinical judgement of the physician treating that patient. The attending physician should make full use of therapeutic drug monitoring (particularly of the aminoglycosides) both to monitor compliance and to avoid toxic effects.

In extremely resistant disease, surgery is sometimes the last port of call. The centre with the largest experience in this is in Denver, Colorado. In 17 years of experience, they have performed 180 operations; of these, 98 were lobectomies, 82 were pneumonectomies. There is a 3.3% operative mortality, with an additional 6.8% dying following the operation; 12% experienced significant morbidity (particularly extreme breathlessness). Of 91 patients who were culture positive before surgery, only 4 were culture positive after surgery.

Thankfully, MDR-TB strains seem to be less fit and less transmissible. It has been known of many years that INH-resistant TB is less virulent in guinea pigs, and the epidemiological evidence is that MDR strains of TB do not dominate naturally. A study in Los Angeles found that only 6% of cases of MDR-TB were clustered. This should not be a cause for complacency: it must be remembered that MDR-TB has a mortality rate comparable to lung cancer.

Patients who fail treatment

Patient who respond to treatment and appeared to be cured after completing a course of TB treatment are not classed as treatment failures, but as relapses and are discussed in a separate section below.

Patients who said to have failed treatment if they fail to respond to treatment (cough and sputum production persisting throughout the whole of treatment), or who only experience a transient response to treatment (who get better at first but then get worse again, all the while on treatment), must be distinguished from patients who relapse (those who get better while on treatment and only get worse again after stopping treatment). Patients who relapse are discussed in a separate section below.

It is very uncommon for patients not to respond to TB treatment at all (even transiently), because this implies resistance at base-line to all of the drugs in the regimen. Patients who fail to get any response at all while on treatment should first of all be questioned very closely about whether or not they have been taking their medicines, and perhaps even be admitted to hospital to be observed taking their treatment. Blood or urine samples may be taken to check for malabsorption. If it can be shown that they are fully compliant with their medication, then the possibility that they have another diagnosis (perhaps in addition to the diagnosis of TB) is very high. These patients should have their diagnosis carefully reviewed and specimens obtained for TB culture and sensitivity testing. Patients who get better and then get worse again should likewise be question very closely about adherence to treatment. If adherence is confirmed then they should be investigated for resistant TB (including MDR-TB), even if a specimen has already been obtained for microbiology before commencing treatment.

Prescription or dispensing errors will account for a proportion of patients who fail to respond to treatment. Immune defects are a rare cause of non-response. In a tiny proportion of patients, treatment failure is a reflection of extreme biological variation and no cause is found.

Treatment of patients who relapse

There is a small relapse rate associated with all treatment regimens, even if the treatment has been taken religiously with 100% compliance (the standard regimen 2HREZ/4HR has a relapse rate fo 2 to 3%). The majority of relapses occur within 6 months of finishing treatment. Patients who are more likely to relapse are those who were took their medication in an unreliable and irregular fashion.

The possibility of resistance is higher in those patients who relapse and every effort must be made to obtain a specimen that can be cultured for sensitivities. That said, most patients who relapse do so with a fully sensitive strain and it is possible that these patients have not relapsed, but have instead been re-infected; these patients can be re-treated with the same regimen as before (no drugs need to be added to the regimen and the duration need not be any longer).

The WHO recommends a regimen of 2SHREZ/6HRE when microbiology is not available (the majority of countries where TB is highly endemic). This regimen was designed to provide optimal treatment for fully-sensitive TB (the most common finding in patients who have relapsed) as well as to cover the possibility of INH-resistant TB (the most common form of resistance found).

The worry about TB relapse should not mean that patients are routinely followed-up after completing a first course of treatment, but all patients should be warned of the symptoms of TB relapse upon finishing treatment and given strict instructions to return to their doctor if symptoms occur.

Trial of TB treatment

In areas where TB is highly endemic, it is not unusual to encounter patient with a fever, but in whom no source of infection is found. The physician may then, after extensive investigation has excludes all other diseases, resort to a trial of TB treatment. The regimen used is HEZ for a minimum of three weeks; RMP is omitted from the regimen because it is a broad spectrum antibiotic, whereas the other three drugs treat only Mycobacterium tuberculosis. Resolution of the fever after three weeks of treatment is good evidence for occult TB and the patient should then be changed to conventional TB treatment (2HREZ/4HR). If the fever does not resolve after three weeks of treatment then it is reasonable to conclude that the patient has another cause for his fever. Endemic, in a broad sense, can mean belonging or native to, characteristic of, or prevalent in a particular geography, race, field, area, or environment; Native to an area or scope. ...

Surgical Treatment of Tuberculosis

Surgery has played an important part in the management of tuberculosis since the 1940's.

Historical surgical management of tuberculosis

The first successful treatments for tuberculosis were all surgical. They were based on the observation that healed tuberculous cavities were all closed. Surgical management was therefore directed at closing open cavities in order to encourage healing. These procedures were all used in the pre-antibiotic era. There exists a myth that surgeons believed that the purpose was to deprive the organism of oxygen: it was however well known that the organism survives anaerobic conditions.

Recurrent or persistent pneumothorax

The simplest and earliest procedure was to introduce air into the pleural space so as to collape the affected lung and therefore the open cavity. There was always spontaneous resolution of the pneumothorax and the procedure had to be repeated every few weeks.

Phrenic nerve crush

The phrenic nerve (which supplies the diaphragm) was cut or crushed so as to permanently paralyse the diaphragm on that side. The paralysed diaphragm would then rise up and the lung on that side would collapse, thus closing the cavity.

Thoracoplasty

When the cavity was located in the apex of the lung, thoracoplasty could be performed. Six to eight ribs were broken and pushed into the thoracic cavity to collapse the lung beneath. This was a disfiguring operation, but it avoided the need for repeated procedures.

Plombage

Plombage reduced the need for a disfiguring operation. It involved inserting porcelain balls into the thoracic cavity to collapse the lung underneath.

Surgical resection of infected lung was not possible in the 1940's and 1950's, because the science of anaesthesia at the time was not sufficiently advanced to permit surgery on the lungs of an anaesthetised patient. The phrenic nerve arises from the third, fourth, and fifth cervical spinal nerves (C3-C5). ... A diaphragm is some sort of separating membrane. ...

Modern surgical treatment of tuberculosis

In modern times, the surgical treatment of tuberculosis is confined to the management of multi-drug resistant TB. A patient with MDR-TB who remains culture positive after many months of treatment may be referred for lobectomy or pneumonectomy with the aim of cutting out the infected tissue. A pneumonectomy (or pneumectomy) is an surgical procedure to remove a lung. ... A pneumonectomy (or pneumectomy) is an surgical procedure to remove a lung. ...

In extrapulmonary TB, surgery is often needed to make a diagnosis (rather than to effect a cure): surgical excision of lymph nodes, drainage of abscesses, tissue biopsy, etc. are all examples of this. Samples taken for TB culture should be sent to the laboratory in a sterile pot with no additive (not water, not saline, or anything) and must arrive in the laboratory as soon as possible. In spinal TB, surgery is indicated for spinal instability (when there is extensive bony destriction) or when the spinal cord is threatened. Therapeutic drainage of tuberculous abscesses or collections is not routinely indicated and will resolve with adequate treatment. In TB meningitis, hydrocephalus is a potential complication and may necessitate the insertion of a ventricular shunt or drain.

Treatment of latent tuberculosis

See latent tuberculosis

The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease. Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ... Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ...

The terms "preventive therapy" and "chemoprophylaxis" have been used for decades and are preferred in the UK because it involves giving medication to people who have no active disease and are currently well. The term "latent tuberculosis treatment" is preferred in the US because the medication does not actually prevent infection: it prevent existing silent infection from becoming active. The feeling in the US is that the term "treatment of LTBI" promotes wider implementation by convincing people that they are receiving treatment for disease. There are no convincing reasons to prefer one term over the other.

The criteria for the diagnosis of latent tuberculosis varies widely from country to country. There is great enthusiasm for the treatment of latent TB in the US, largely because the US has never adopted the routine use of BCG. Following the US criteria for LTBI results in many more people being diagnosed (possibly erroneously). Following the current UK criteria results in a much smaller number of people being targeted for chemoprophylaxis; importantly, UK guidelines do not allow for the treatment of people aged 35 and over because of the significantly increased risk of potentially fatal drug-induced side effects in someone who is otherwise well. There are good arguments to support both views. It may be argued that the UK approach results in a greater number of untreated people; but to compensate for this, UK guidelines recommend extended follow-up or BCG-vaccination for many of these people. A comparison of the UK and US guidelines is given in the article on latent tuberculosis. Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ...

It is essential that assessment to rule out active TB is carried out before treatment for LTBI is started. It is a serious error giving LTBI treatment to someone with active TB.

There are several treatment regimens available:

• 9H—Isoniazid for 9 months is the gold standard and is 93% effective.
• 6H—Isoniazid for 6 months might be adopted by a local TB program based on cost-effectiveness and patient compliance. This is the regimen currently recommended in the UK for routine use. The US guidance exclude this regimen from use in children or persons with radiographic evidence of prior tuberculosis (old fibrotic lesions). (69% effective)
• A twice-weekly regimen for the above 2 treatment regimens is an alternative if administered under Directly observed therapy (DOT).
• 4R—Rifampin for 4-months is an alternative for those who are unable to take isoniazid or pyrazinamide.
• 2RZ—The two month regimen of rifampin and pyrazinamide is no longer recommended for treatment of LTBI because of the greatly increased risk of drug-induced hepatitis.

Treatment Regimen Chart adopted from Table 10 of Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (see References) Isoniazid is a first-line antituberculous medication used in the prevention and treatment of tuberculosis. ... Directly Observed Treatment (DOT) or Directly Observed Therapy is watching the patient take his/her medication to ensure medications are taken in the right combination and for the correct duration. ... Rifampicin (INN) or rifampin (USAN) is an antibiotic drug of the rifamycin group. ... Rifampicin (INN) or rifampin (USAN) is an antibiotic drug of the rifamycin group. ... Pyrazinamide is an antituberculosis agent used to treat tuberculosis in afflicted patients. ...

Since about 10% of latent TB infection progresses to active TB disease, the 9H treatment regimen reduces the 10% risk to less than 1%, and the 6H regimen reduces it to 3%.

Links

Wikipedia articles

• Tuberculosis
• Mycobacterium tuberculosis
• Latent tuberculosis
• Mantoux test
• Heaf test

Tuberculosis (commonly shortened to TB) is an infection caused by the bacterium Mycobacterium tuberculosis, which most commonly affects the lungs (pulmonary TB) but can also affect the central nervous system (meningitis), lymphatic system, circulatory system (Miliary tuberculosis), genitourinary system, bones and joints. ... Binomial name Mycobacterium tuberculosis Zopf 1883 Mycobacterium tuberculosis is the bacterium that causes most cases of tuberculosis[1]. It was first described on March 24, 1882 by Robert Koch, who subsequently received the Nobel Prize in physiology or medicine for this discovery in 1905. ... Also called latent tuberculosis infection, latent TB or LTBI. Latent tuberculosis is where a patient is infected with Mycobacterium tuberculosis, but does not have active tuberculosis disease. ... The Mantoux test is a skin test of tuberculosis infection used in the United States and is endorsed by the American Thoracic Society and Centers for Disease Control and Prevention (CDC). ... The Heaf test is a diagnostic skin test performed in order to determine whether or not a child has been exposed to tuberculosis. ...

Published guidelines

• ↑  National Institute for Health and Clinical Excellence (UK) (2006). "Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control"
• ↑  Joint Tuberculosis Committee of the British Thoracic Society (2000). "Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000". Thorax 55 (11): 887–901. PMID 11050256.
• ↑  World Health Organisation (2003). "Treatment of Tuberculosis: Guidelines for National Programmes"
• ↑  American Thoracic Society, Center for Disease Control, Infectious Diseases Society of America (2003). "Treatment of Tuberculosis"
• ↑  American Thoracic Society, Center for Disease Control (2000). "Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection"

References

1. ↑ Medical Research Council Streptomycin in Tuberculosis Trials Committee (1948). "Streptomycin treatment for pulmonary tuberculosis". Brit Med J ii: 769–82.
2. ↑ David H. L. (1970). "Probability Distribution of Drug-Resistant Mutants in Unselected Populations of Mycobacterium tuberculosis". Appl Microbiol 20 (5): 810-4. PMID 4991927.
3. ↑ British Thoracic Society (1984). "A controlled trial fo six months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond.". Brit J Diseases Chest 78 (4): 330–36. PMID 6386028.
4. ↑ Ormerod LP, Horsfield N (1987). "Short-course antituberculous chemotherapy for pulmonary and pleural disease: five years' experience in clinical practice". Brit J Diseases Chest 81 (3): 268–71.
5. ↑ Teoh R, O'Mahony G, Yeung VTF (1986). "Polymorphonuclear pleocytosis in the cerebrospinal fluid during chemotherapy for tuberculous meningitis". J Neurol 233 (4): 237-41.
6. ↑ Chang AB et al (1998). "Central nervous system tuberculosis after resolution of miliary tuberculosis". Pediatr Infect Dis J 17 (6): 519-523. PMID 9655548.
7. ↑ Thwaites GE et al. (2004). "Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults". N Engl J Med 351 (17): 1741–51. PMID 15496623.
8. ↑ Roberts MT, Mendelson M, Meyer P, Carmichael A, Lever AM (2003). "The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports". J Infect 47 (3): 251–5. PMID 12963389.
9. ↑ Yee D et al. (2003). "Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis". Am J Resp Crit Care Med 167 (11): 1472–7. PMID 12569078.
10. ↑ Ormerod L. P., Horsfield N. (1996). "Frequency and type of reactions to antituberculosis drugs: observations in routine treatment" 77 (1): 37–42. PMID 8733412.
11. ↑ Steel M. A., Burk R. F., DesPrez R. M. (1991). "Toxic hepatitis with isoniazid and rifampin: a meta-analysis". Chest 99 (2): 465-471. PMID 1824929.
12. ↑ Center for Disease Control (2006). "Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004". MMWR Weekly 55 (11): 301–305.
13. ↑ Mitnick C et al. (2003). "Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru". N Eng J Med 348 (2): 119-128. PMID 12519922.
14. ↑ Leimane V., et al. (2005). "Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study". Lancet 365 (9456): 318-26. PMID 15664227.

This article contains material from the CDC (Center for Disease Control) website which, as a US government publication, is in the public domain. The public domain comprises the body of all creative works and other knowledge—writing, artwork, music, science, inventions, and others—in which no person or organization has any proprietary interest. ...